SFL Pharma places prescription drugs onto the Swiss market, with a special focus on orphan drugs. Rare (or "orphan") diseases are life-threatening or chronically debilitating diseases that occur in less than 5 in 10,000 people in the Swiss community. There are approximately 7,000 rare diseases that may affect around 500,000 people in Switzerland.